1 Division of Vascular and Interventional Radiology, Department of Radiology, WCC 308-F, Beth Israel Deaconess Medical Center/Harvard Medical School, 1 Deaconess Rd, Boston, MA 02215.
AJR Am J Roentgenol. 2018 Jun;210(6):1368-1375. doi: 10.2214/AJR.17.18695. Epub 2018 Apr 27.
The purpose of this article is to discuss the use, comparative efficacy, and general technical considerations of percutaneous ablation, alone or in combination with other therapies, for the treatment of hepatocellular carcinoma (HCC).
Percutaneous ablation is a mainstay treatment for early-stage HCC, offering survival comparable to that of surgical resection for small lesions. It can act as a primary curative therapy or bridge therapy for patients waiting to undergo liver transplant. New ablation modalities and combining tumor ablation with other therapies, such as transarterial chemoembolization, can improve clinical outcomes and allow treatment of larger lesions. Combining thermal ablation with systemic chemotherapy, including immunotherapy, is an area of future development.
本文旨在讨论单独或联合其他疗法应用经皮消融治疗肝细胞癌（HCC）的方法、疗效比较和一般技术注意事项。
经皮消融是早期 HCC 的主要治疗方法，对于小肿瘤，其生存结果可与手术切除相媲美。它可以作为肝移植等待患者的主要治愈性或桥接治疗方法。新的消融方式以及将肿瘤消融与其他疗法（如经动脉化疗栓塞）相结合可以改善临床结果，并允许治疗更大的肿瘤。将热消融与包括免疫疗法在内的全身化疗相结合是未来的发展方向。
